Can, EsraÖlmez, FatmaBulut, HuriOğlak, Süleyman Cemil2022-06-162022-06-162022Can E, Cemil Oğlak S, Ölmez F, Bulut H. Serum neutrophil gelatinase-associated lipocalin concentrations are significantly associated with the severity of COVID-19 in pregnant patients. Saudi Med J. 2022 Jun;43(6):559-566. doi: 10.15537/smj.2022.43.6.20220156. PMID: 35675933.0379-5284http://doi.org/10.15537/smj.2022.43.6.20220156https://hdl.handle.net/20.500.12713/2906Objectives: To evaluate serum neutrophil gelatinaseassociated lipocalin (NGAL) concentrations of pregnant women complicated with coronavirus disease 2019 (COVID-19) and investigate its diagnostic value for the severity of COVID-19. Methods: Of the 46 pregnant women with COVID-19 included in the study, we further classified these women into 2 subgroups: the non-severe COVID-19 group (n=25) and the severe COVID-19 group (n=21). Results: Neutrophil gelatinase-associated lipocalin plasma concentrations were significantly higher in pregnant women complicated with severe COVID-19 (90 [53.1-207.7] ng/ml) compared to those from Original Article pregnant women with non-severe COVID-19 (51.8 [39.6-70.3] ng/ml) and healthy pregnant women (44.3 [32.2-54.1] ng/ml, p<0.001). Also, at a cutoff value of 72 ng/ml, NGAL predicted severe COVID-19 with a sensitivity rate of 57% and a specificity rate of 84%. Serum NGAL level (adjusted hazard ratio [aHR]=1.020, 95% confidence interval [CI]= [1.006-1.035], p=0.007), and D-dimer level (aHR=2.371, 95% CI= [1.085-5.181], p=0.030) were the variables that were revealed to be significantly associated with the disease severity. Conclusion: We demonstrated that NGAL was highly associated with COVID-19 severity. We consider that NGAL might be a useful biomarker to diagnose the disease severity in patients with COVID-19.eninfo:eu-repo/semantics/openAccessCOVID-19Disease SeverityNeutrophil Gelatinase-Associated LipocalinArticle43655956635675933WOS:0008113309000032-s2.0-85131648254Q310.15537/smj.2022.43.6.20220156Q3